Skip to content
Open access

N-salicyloyl tryptamine derivatives as potential therapeutic agents for doxorubicin-induced hepatotoxicity via PI3K/AKT/HO-1 signaling pathway

Sep 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 40 references
Medicine

TL;DR

A50 may alleviated DOX-induced hepatotoxicity by activating the PI3K/AKT/HO-1 pathway to inhibit oxidative stress-driven pathological processes, including mitochondrial dysfunction, inflammation, and apoptosis.

Abstract

Doxorubicin (DOX) is a broad-spectrum antineoplastic agent with remarkable efficacy against various malignant tumors. However, its clinical application is severely limited by profound hepatotoxicity, wherein oxidative stress acts as a pivotal mechanism underlying DOX-induced hepatotoxicity. N-salicyloyl tryptamine derivatives (NSTs) have been reported to possess potent antioxidant activities. In the present study, NSTs were applied for the first time in DOX-induced hepatotoxicity with structural modifications to the scaffold. Through systematic screening, a novel compound A50 was identified as the most potent active candidate. Both in vitro (AML12 cell lines) and in vivo (mice model of DOX-induced hepatotoxicity) experiments demonstrated that A50 significantly enhanced superoxide dismutase (SOD) activity, reduced malondialdehyde (MDA) levels, stabilized mitochondrial membrane potential (MMP), and promoted adenosine triphosphate (ATP) production, thus effectively improving mitochondrial function and suppressing oxidative stress-mediated damage. Additionally, A50 decreased serum levels of liver injury biomarkers [alanine transaminase (ALT), aspartate transaminase (AST) and levels of proinflammatory cytokines [tumor necrosis factor-αα (TNF-α), interleukin-6 (IL-6)], inhibited lactate dehydrogenase (LDH) activity, and attenuated histopathological lesions in liver tissues, without affecting its anti-hepatocellular carcinoma activity. Mechanism investigations revealed the hepatoprotective effects of A50 were associated with activation of the PI3K/AKT/HO-1 signaling pathway, and these effects could be blocked by the PI3K-specific inhibitor LY294002 in vitro. In conclusion, A50 may alleviated DOX-induced hepatotoxicity by activating the PI3K/AKT/HO-1 pathway to inhibit oxidative stress-driven pathological processes, including mitochondrial dysfunction, inflammation, and apoptosis. These findings highlight A50 as a promising candidate for the treatment of DOX-induced hepatotoxicity.

Read PDF

Similar papers

Open access Oct 2026

Ursolic acid sensitizes hepatoma cells to sulfasalazine-induced ferroptosis via AMPK/BECN1/SLC7A11-mediated redox disruption in vitro and in vivo

Targeting ferroptosis has emerged as a promising anti-cancer strategy. A Food and Drug Administration (FDA)-approved drug, sulfasalazine (SAS), also a ferroptosis inducer, is being explored as a potential treatment drug for cancer. However, long-term high-dose SAS treatment may induce several adverse effects in the...

Kai Han, Jia-Yuan Li, Bing-Ying Shuai et al. · 0 citations
Sep 2026

Acteoside ameliorates doxorubicin-induced cardiotoxicity by suppressing ferroptosis through activation of the KEAP1/NRF2 pathway.

Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major limitation to the clinical use of DOX, highlighting the need for effective cardioprotective strategies. Although acteoside (ACT), a natural compound with antioxidant properties, has shown potential cardioprotective effects, its role in DIC, particularly in the r...

Meng Wang, Che Wang, Zhi-Hao Liu et al. · 0 citations
Open access Oct 2026

Design, synthesis of a novel ginsenoside derivative and its protection against acetaminophen induced liver injury via suppressing HIF1α-mediated glycolytic metabolism.

Background Acetaminophen (APAP) overdose is a leading cause of drug-induced liver injury (DILI). Inspired by the synergistic hepatoprotective effects of (20S, 24R)-ocotillol (OC) and lipoic acid (LA), we designed and synthesized OCLA, a novel ginsenoside derivative that has been granted a patent. Methods The structur...

Han Liu, Qiu-Yue Zhang, Wei Shang et al. · 0 citations
Sep 2026

Methyl Jasmonate Attenuates Doxorubicin-induced Myocardial Damage Through Multifaceted Cellular and Molecular Mechanisms: An Integrated In Vitro, In Vivo Approach.

INTRODUCTION Doxorubicin (Dox) is a widely used antineoplastic drug that often causes cardiomyopathy, leading to congestive heart failure through the production of Reactive Oxygen Species (ROS) within the myocardium. This investigation examines the protective effects of Methyl Jasmonate (MeJA) against Dox-induced cardi...

Ujwal N. Katolkar, S. Surana · 0 citations
Open access Sep 2026

Fused Azine Derivatives Mitigate Long-Term Paracetamol-Induced Liver Fibrosis in Mice: Role of JNK1/ASK1 and Nrf2/HO-1 Signaling Pathways

The administration of newly synthesized fused azine derivative compounds successfully reduced APAP-induced hepatic fibrosis through decreasing serum liver enzymes, as well as the hepatic pathological deterioration and effectively ameliorated the inflammatory response.

Ahmed Shawky, Heba A. Metwaly, Hanan M. Ragab et al. · 0 citations
Oct 2026

Olea europaea leaf extract mitigates doxorubicin-induced hepatotoxicity associated with modulation of oxidative stress, inflammation, and apoptosis: Integrated biochemical, molecular, and histopathological evidence.

BACKGROUND Doxorubicin (DOX) is an effective antineoplastic agent whose clinical use is limited by hepatotoxicity. This study evaluated the hepatoprotective effects of Olea europaea leaf extract (OLE) in a rat model of DOX -induced hepatotoxicity. METHODS Thirty-two male Wistar rats were randomly assigned to four gro...

M. Ibrahim, A. Khalifa, Rania A. Galhom et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.